Singulair 4mg 28 chewable tablets — Made in Great Britain — Free Delivery

Singular® chewable tablets are used for the following indications:

Hypersensitivity to any component of the preparation.

The therapeutic effect of the preparation "Singular®" on the parameters of asthma control occurs within one day. Patients should be advised to continue taking Singulair® even if asthma control is achieved, as well as during periods of asthma exacerbation.

There is no need for dose adjustment for patients with impaired renal function or with mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage for boys and girls is the same.

As an alternative treatment for low-dose inhaled corticosteroids for persistent mild asthma

Montelukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast as an alternative to low-dose inhaled corticosteroids in children with persistent mild asthma should only be considered in patients who have not had a recent severe asthma attack requiring oral corticosteroids and who cannot use inhaled corticosteroids. Mild persistent asthma is defined as the occurrence of asthma symptoms more than once a week but less than once a day, the occurrence of nocturnal symptoms more than twice a month but less than once a week, and normal lung function between episodes. If sufficient asthma control is not achieved further (usually within one month), the need for additional or other anti-inflammatory therapy should be determined based on a consistent asthma management system. Patients should be periodically assessed for asthma control.

There is no special information on the treatment of an overdose with the preparation "Singular®". In studies of chronic asthma, montelukast was prescribed in doses up to 200 mg / day to adult patients for 22 weeks, and in short-term studies - up to 900 mg / day for about one week, while clinically important adverse reactions did not occur. In post-marketing use and in clinical trials, there have been reports of acute overdose of the preparation "Singular®". These included the administration of the preparation in adults and children in doses exceeding 1000 mg (approximately 61 mg / kg in a child aged 42 months). The obtained clinical and laboratory data were consistent with the safety profile in adult patients and children. In most cases of overdose, no adverse reactions were reported. The most common adverse reactions were observed, which corresponded to the safety profile of the preparation "Singular" and included: abdominal pain, drowsiness, thirst, headache, vomiting and psychomotor hyperactivity.

It is not known whether montelukast is excreted by peritoneal dialysis or hemodialysis.

Montelukast has been evaluated in clinical trials: chewable tablets 5 mg were used by approximately 1,750 children aged 6 to 14 years.

In clinical studies, the following adverse reactions were observed frequently (from? 1/100 to <1/10) in patients treated with montelukast, and also with a greater frequency than in patients treated with placebo.

Nervous system disorders: headache.